Results: 1-25 | 26-50 | 51-75 | 76-100 | >>

Table of contents of journal: *Alimentary pharmacology and therapeutics

Results: 51-75/1697

Authors: O'Mahony, L Feeney, M O'Halloran, S Murphy, L Kiely, B Fitzgibbon, J Lee, G O'Sullivan, G Shanahan, F Collins, JK
Citation: L. O'Mahony et al., Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice, ALIM PHARM, 15(8), 2001, pp. 1219-1225

Authors: Plattner, V Leray, V Leclair, MD Aube, AC Cherbut, C Galmiche, JP
Citation: V. Plattner et al., Interleukin-8 increases acetylcholine response of rat intestinal segments, ALIM PHARM, 15(8), 2001, pp. 1227-1232

Authors: Nogi, K Haruma, K Taniguchi, H Yomota, E Okajima, M Hananoki, M Hata, J Kusunoki, H Onoda, Y
Citation: K. Nogi et al., Duodenogastric reflux following cholecystectomy in the dog: role of antroduodenal motor function, ALIM PHARM, 15(8), 2001, pp. 1233-1238

Authors: Cook, TA Brading, AF Mortensen, NJM
Citation: Ta. Cook et al., Review article: the pharmacology of the internal anal sphincter and new treatments of ano-rectal disorders T., ALIM PHARM, 15(7), 2001, pp. 887-898

Authors: Selvasekar, CR Birbeck, N Mcmillan, T Wainwright, M Walker, SJ
Citation: Cr. Selvasekar et al., Review article: photodynamic therapy and the alimentary tract, ALIM PHARM, 15(7), 2001, pp. 899-915

Authors: Gisbert, JP Gonzalez, L Calvet, X Roque, M Gabriel, R Pajares, JM
Citation: Jp. Gisbert et al., Proton pump inhibitors versus H-2-antagonists: a meta-anaiysis of their efficacy in treating bleeding peptic ulcer, ALIM PHARM, 15(7), 2001, pp. 917-926

Authors: Vakil, NB Shaker, R Johnson, DA Kovacs, T Baerg, RD Hwang, C D'Amico, D Hamelin, B
Citation: Nb. Vakil et al., The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety, ALIM PHARM, 15(7), 2001, pp. 927-935

Authors: Appel-Dingemanse, A Horowitz, A Campestrini, J Osborne, S McLeod, J
Citation: A. Appel-dingemanse et al., The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects - male and female, elderly and young, ALIM PHARM, 15(7), 2001, pp. 937-944

Authors: Soni, A Sonnenberg, A
Citation: A. Soni et A. Sonnenberg, Healthcare resource utilization in the management of oesophageal adenocarcinoma, ALIM PHARM, 15(7), 2001, pp. 945-951

Authors: Di Marco, V Vaccaro, A Ferraro, D Alaimo, G Rodolico, V Parisi, P Peralta, S Di Stefano, R Almasio, PL Craxi, A
Citation: V. Di Marco et al., High-dose prolonged combination therapy in non-responders to interferon monotherapy for chronic hepatitis C, ALIM PHARM, 15(7), 2001, pp. 953-958

Authors: Longstreth, GF Hawkey, CJ Mayer, EA Jones, RH Naesdal, J Wilson, IK Peacock, RA Wiklund, IK
Citation: Gf. Longstreth et al., Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials, ALIM PHARM, 15(7), 2001, pp. 959-964

Authors: Testoni, PA Bagnolo, F Andriulli, A Bernasconi, G Crotta, S Lella, F Lomazzi, A Minoli, G Natale, C Prada, A Toti, GL Zambelli, A
Citation: Pa. Testoni et al., Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: results of a multicenter, randomized, controlled trial, ALIM PHARM, 15(7), 2001, pp. 965-972

Authors: Kelly, P Musuku, J Kafwembe, E Libby, G Zulu, I Murphy, J Farthing, MJG
Citation: P. Kelly et al., Impaired bioavailability of vitamin A in adults and children with persistent diarrhoea in Zambia, ALIM PHARM, 15(7), 2001, pp. 973-979

Authors: Shaw, MJ Beebe, TJ Adlis, SA Talley, NJ
Citation: Mj. Shaw et al., Reliability and validity of the digestive health status instrument in samples of community, primary care, and gastroenterology patients, ALIM PHARM, 15(7), 2001, pp. 981-987

Authors: Konturek, PC Konturek, SJ Sulekova, Z Meixner, H Bielanski, W Starzynska, T Karczewska, E Marlicz, K Stachura, J Hahn, EG
Citation: Pc. Konturek et al., Expression of hepatocyte growth factor, transforming growth factor alpha, apoptosis related proteins Bax and Bcl-2, and gastrin in human gastric cancer, ALIM PHARM, 15(7), 2001, pp. 989-999

Authors: Bazzoli, F Palli, D Zagari, RM Festi, D Pozzato, P Nicolini, G Masala, G Fossi, S Ricciardiello, L Panuccio, D Roda, E
Citation: F. Bazzoli et al., The Loiano-Monghidoro population-based study of Helicobacter pylori infection: prevalence by C-13-urea breath test and associated factors, ALIM PHARM, 15(7), 2001, pp. 1001-1007

Authors: You, JHS Lee, KKC Ho, SSS Sung, JJY Kung, NNS Yung, M Lee, C Yee, GC
Citation: Jhs. You et al., Economic analysis of four triple regimens for the treatment of Helicobacter pylori-related peptic ulcer disease in in-patient and out-patient settings in Hong Kong, ALIM PHARM, 15(7), 2001, pp. 1009-1015

Authors: Perri, F Villani, MR Quitadamo, M Annese, V Niro, GA Andriulli, A
Citation: F. Perri et al., Ranitidine bismuth citrate-based triple therapies after failure of the standard 'Maastricht triple therapy': a promising alternative to the quadrupletherapy?, ALIM PHARM, 15(7), 2001, pp. 1017-1022

Authors: Perri, F Villani, MR Festa, V Quitadamo, M Andriulli, A
Citation: F. Perri et al., Predictors of failure of Helicobacter pylori eradication with the standard'Maastricht triple therapy', ALIM PHARM, 15(7), 2001, pp. 1023-1029

Authors: Pilotto, A Franceschi, M Leandro, G Bozzola, L Rassu, M Soffiati, G Di Mario, F Valerio, G
Citation: A. Pilotto et al., Cure of Helicobacter pylori infection in elderly patients: comparison of low versus high doses of clarithromycin in combination with amoxicillin and pantoprazole, ALIM PHARM, 15(7), 2001, pp. 1031-1036

Authors: Tepes, B Krizman, I Gorensek, M Gubina, M Orel, I
Citation: B. Tepes et al., Is a one-week course of triple anti-Helicobacter pylori therapy sufficientto control active duodenal ulcer?, ALIM PHARM, 15(7), 2001, pp. 1037-1045

Authors: Hurenkamp, GJB Grundmeijer, HGLM Van der Ende, A Tytgat, GNJ Assendelft, WJJ Van der Hulst, RWM
Citation: Gjb. Hurenkamp et al., Arrest of chronic acid suppressant drug use after successful Helicobacter pylori eradication in patients with peptic ulcer disease: a six-month follow-up study, ALIM PHARM, 15(7), 2001, pp. 1047-1054

Authors: Laheij, RJF Jansen, JBMJ Verbeek, ALM Verheugt, FWA
Citation: Rjf. Laheij et al., Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease, ALIM PHARM, 15(7), 2001, pp. 1055-1059

Authors: Calvet, X Garcia, N Gene, E Campo, R Brullet, E Sanfeliu, I
Citation: X. Calvet et al., Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment, ALIM PHARM, 15(7), 2001, pp. 1061-1065

Authors: Calvet, X Gene, E Lopez, T Gisbert, JP
Citation: X. Calvet et al., What is the optimal length of proton pump inhibitor-based triple therapiesfor H-pylori? A cost-effectiveness analysis, ALIM PHARM, 15(7), 2001, pp. 1067-1076
Risultati: 1-25 | 26-50 | 51-75 | 76-100 | >>